title: [Successful treatment with CPT-11 and adriamycin for hemophagocytic syndrome associated with intravascular lymphomatosis].
abstract: A 75-year-old man was admitted because of non-Hodgkin's lymphoma (histology undetermined) of the rib. A complete remission was achieved after CHOP therapy and irradiation. One year later, high fever, thrombocytopenia and liver dysfunction developed. Bone marrow aspirate revealed a hypoplastic marrow with hemophagocytic histiocytes, and a diagnosis of hemophagocytic syndrome (HPS) was made. Although no lymphomatous lesions were detected, HPS due to relapsed lymphoma was strongly suspected. The patient received MEVP therapy including etoposide and prednisolone, but without any improvement. Soon after the initiation of CPT-11 and adriamycin (ADM) therapy, all symptoms of HPS disappeared. This combination chemotherapy was repeated over a three-week span, and the patient remained in partial remission for the next 10 months. In November 1997, a tumor developed in the paranasal sinus, and the patient died three months later. The autopsy disclosed many B lymphoma cells filling the small vessels of almost all organs, and a final diagnosis of intravascular lymphomatosis (IVL) was made. These findings indicate that combination CPT-11 and ADM therapy is effective for cases of IVL accompanied by HPS that are refractory to conventional chemotherapies.
authors.affiliation: Division of Hematology-Chemotherapy, Chiba Cancer Center Hospital.
authors.forename: M
authors.initials: M
authors.lastname: Ise
authors.forename: C
authors.initials: C
authors.lastname: Sakai
authors.forename: H
authors.initials: H
authors.lastname: Tsujimura
authors.forename: K
authors.initials: K
authors.lastname: Kumagai
authors.forename: T
authors.initials: T
authors.lastname: Takenouchi
authors.forename: T
authors.initials: T
authors.lastname: Takagi
mesh_terms: D000368:Aged; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D002166:Camptothecin / Q000008:administration & dosage / Q000031:analogs & derivatives*; D004317:Doxorubicin / Q000008:administration & dosage*; D015616:Histiocytosis, Non-Langerhans-Cell / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D000077146:Irinotecan; D008228:Lymphoma, Non-Hodgkin / Q000150:complications*; D008297:Male; D019043:Vascular Neoplasms / Q000150:complications*
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D000077146:Irinotecan; D004317:Doxorubicin; D002166:Camptothecin